View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
MarketLine Department
  • MarketLine Department

Bruker Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances

Summary Marketline's Bruker Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bruker Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports off...

Danaher Corp: 1 director

A director at Danaher Corp sold/sold after exercising options 34,688 shares at 236.587USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

Danaher Corporation - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Danaher Corporation: Update following outlook change to positive

Our credit view of this issuer reflects its considerable size and scale in the global life sciences markets, tempered by appetite for moderately high financial leverage.

MarketLine Department
  • MarketLine Department

Bruker Corp - Company Profile and SWOT Analysis

Summary Bruker Corp - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bruker Corp (Bruker) designs, manufactures and sells scientific instruments, and analytical and diagnostic solutions. The company's product portfolio includes mass spectrometry technologies, microtomography...

Danaher Corporation: Strong cash flow to continue while managing slowe...

Our credit view of this issuer reflects its diversified revenue base, geographic diversification and leading market position.

Moody's: Danaher's acquisition of Abcam enhances business profile and ...

Moody's Investors Service commented that Danaher Corporation's announcement that it will acquire Abcam plc for approximately $5.7 billion is positive for the Danaher's business profile and growth rates. There is no impact on Danaher's A3 rating or its stable outlook. For additional information ple...

Danaher Corporation: Abcam acquisition will enhance business profile a...

The acquisition will expand Danaher's range of consumable life sciences products and deepen its relationships with biopharmaceutical companies.

Danaher Corporation - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sartorius Stedim - 20% Below 2024 Cons. EBITDA (SELL, TP EUR170, 9 pgs...

Our analysis of the order book leads us to believe that revenue guidance is almost impossible to hit without 20% revenue growth in Q423. Much more worryingly, mgmt admitted to adding 50% to capacity in terms of revenues which will start to come on stream in Q4, this year. When there is already excess capacity & SSB’s Q2 gross margin was the weakest in >5yrs driven by lower utilisation, the recent rally is a clear selling opportunity in our view. Today’s Danaher revenue guidance downgrade also do...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Global CDMOs - Overcapacity is Coming (Thematic Research)

We have calculated the significant supply about to enter the biologics manufacturing space & analysed demand growth. Whilst the market assumes an improvement in utilisation from 2024, we forecast there will be significant overcapacity in the coming years resulting in even lower utilisation at an industry level. Our detailed bottom-up analysis shows that total mammalian cell supply is set to grow by 11% p.a. 2023-26 but demand is set to grow just 8% p.a. over the same period. However, much more c...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Danaher Corporation: Update to credit analysis following upgrade to A3

Our credit view of this issuer reflects its considerable size and scale in the global life sciences markets, tempered by an aggressive acquisition appetite.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch